Mike McCully

Mike McCully is an experienced biopharma executive, investor, and entrepreneur. He is currently President & CEO of Gate Neurosciences. Over the past 20 years, he has contributed to the development of dozens of successful biotech companies. Mike established his career in the biotech industry in the early 2000’s at the boutique biotech advisory firm Recombinant Capital, Inc. During his tenure, Mike served as an advisor to over 100 companies, including emerging and established biopharma, and had a role in more than $4 billion in partnering transactions. In 2008, Recombinant Capital was acquired by Deloitte and Mike became a Leader in the Deloitte Life Sciences Practice, advising clients on corporate strategy and strategic transactions, based in San Francisco. In 2010, Mike left Deloitte to pursue interests as an entrepreneur, and formed Red Leaf Bioventures LLC. He held several operating roles with emerging biotechs including serving as the head of business development for ForSight Labs (led $632M partnership with Genentech). Mike then joined Elan Pharmaceuticals as Head of Business Development for the BioNeurology Unit (led the formation of the Cambridge-Elan Centre for Research Innovation and Drug Discovery). Mike was an early employee and head of Financial Strategy at Coherus Biosciences (CHRS), a platform biosimilar company, and then served as Chief Business Officer of the pain-focused specialty pharma Charleston Laboratories, where he led the $650M US partnership with Daiichi Sankyo. Most recently, Mike was the Chief Executive Officer of Anagin, Inc., an emerging biotech developing first-inclass novel targeted therapies for addressing pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases. Mike has a BS from Purdue University and MS from Northwestern University.